AI eye exam: a new hope for early glaucoma detection?

NCT ID NCT07758569

Recruiting now Diagnosis Sponsor: Democritus University of Thrace Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether an artificial intelligence system, part of the DDART medical device, can accurately detect signs of glaucoma in retinal photographs. Researchers will compare the AI's readings against confirmed diagnoses from eye specialists using images from 2,000 adults. The goal is to see if this technology could serve as a reliable screening tool for glaucoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence subsystem of the DDART medical device analyzing color retinal fundus photographs
What this could lead to: If successful, this AI could help doctors spot glaucoma earlier and more accurately from routine eye photos, potentially preventing vision loss.
What could go wrong: The AI may not perform as well in real-world settings, and the trial's reliance on high-quality images and specialist-confirmed diagnoses might not reflect everyday conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA

Contacts and locations

Locations

University Hospital of Alexandroupolis
RECRUITING

Alexandroupoli, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.